176 related articles for article (PubMed ID: 34787059)
1. Expression characteristic of
Zhang W; Zhang L; Qian J; Lin J; Chen Q; Yuan Q; Zhou J; Zhang T; Shi J; Zhou H
Bioengineered; 2021 Dec; 12(2):11987-12002. PubMed ID: 34787059
[No Abstract] [Full Text] [Related]
2. Cloning and characterization of porcine 4Ig-B7-H3: a potent inhibitor of porcine T-cell activation.
Chen W; Hou Z; Li C; Xiong S; Liu H
PLoS One; 2011; 6(6):e21341. PubMed ID: 21738638
[TBL] [Abstract][Full Text] [Related]
3. B7-H3 protein expression in acute myeloid leukemia.
Guery T; Roumier C; Berthon C; Renneville A; Preudhomme C; Quesnel B
Cancer Med; 2015 Dec; 4(12):1879-83. PubMed ID: 26376842
[TBL] [Abstract][Full Text] [Related]
4. Dimerization of the 4Ig isoform of B7-H3 in tumor cells mediates enhanced proliferation and tumorigenic signaling.
Sutton MN; Glazer SE; Muzzioli R; Yang P; Gammon ST; Piwnica-Worms D
Commun Biol; 2024 Jan; 7(1):21. PubMed ID: 38182652
[TBL] [Abstract][Full Text] [Related]
5. Expression of costimulatory molecule B7-H3 and its prognostic implications in human acute leukemia.
Hu Y; Lv X; Wu Y; Xu J; Wang L; Chen W; Zhang W; Li J; Zhang S; Qiu H
Hematology; 2015 May; 20(4):187-95. PubMed ID: 25130683
[TBL] [Abstract][Full Text] [Related]
6. Integrated analysis reveals distinct molecular, clinical, and immunological features of B7-H3 in acute myeloid leukemia.
Zhang LY; Jin Y; Xia PH; Lin J; Ma JC; Li T; Liu ZQ; Xiang HL; Cheng C; Xu ZJ; Zhou H; Qian J
Cancer Med; 2021 Nov; 10(21):7831-7846. PubMed ID: 34562306
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
Lichtman EI; Du H; Shou P; Song F; Suzuki K; Ahn S; Li G; Ferrone S; Su L; Savoldo B; Dotti G
Clin Cancer Res; 2021 Jun; 27(11):3141-3153. PubMed ID: 33531429
[TBL] [Abstract][Full Text] [Related]
8. Methylation-independent ITGA2 overexpression is associated with poor prognosis in de novo acute myeloid leukemia.
Lian XY; Zhang W; Wu DH; Ma JC; Zhou JD; Zhang ZH; Wen XM; Xu ZJ; Lin J; Qian J
J Cell Physiol; 2018 Dec; 233(12):9584-9593. PubMed ID: 30132837
[TBL] [Abstract][Full Text] [Related]
9. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
10. DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia.
Sun GK; Tang LJ; Zhou JD; Xu ZJ; Yang L; Yuan Q; Ma JC; Liu XH; Lin J; Qian J; Yao DM
Cancer Med; 2019 Oct; 8(14):6393-6402. PubMed ID: 31486300
[TBL] [Abstract][Full Text] [Related]
11. [Correlation of FLT3 gene expression level and internal tandem duplication mutation in acute myeloid leukemia and its clinical significance].
Wang YG; Liu XH; Liang Y; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):741-5. PubMed ID: 19176010
[TBL] [Abstract][Full Text] [Related]
12. Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia.
Lian XY; Ma JC; Zhou JD; Zhang TJ; Wu DH; Deng ZQ; Zhang ZH; Li XX; He PF; Yan Y; Lin J; Qian J
J Cell Physiol; 2019 Jun; 234(6):9438-9446. PubMed ID: 30317626
[TBL] [Abstract][Full Text] [Related]
13. [The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].
Liu YR; Chang Y; Ruan GR; Qin YZ; Lai YY; Shi HX; Wang YZ; Li LD; Jiang B; Li JL
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):98-103. PubMed ID: 23611213
[TBL] [Abstract][Full Text] [Related]
14. DLX4 hypermethylation is a prognostically adverse indicator in de novo acute myeloid leukemia.
Zhou JD; Zhang TJ; Wang YX; Yang DQ; Yang L; Ma JC; Wen XM; Yang J; Lin J; Qian J
Tumour Biol; 2016 Jul; 37(7):8951-60. PubMed ID: 26753961
[TBL] [Abstract][Full Text] [Related]
15. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of pseudogene Vimentin 2p is associated with poor outcome in de novo acute myeloid leukemia.
Zhai LL; Zhou J; Zhang J; Tang X; Zhou LY; Yin JY; Vanessa MD; Peng W; Lin J; Deng ZQ
Cancer Biomark; 2017; 18(3):305-312. PubMed ID: 28106537
[TBL] [Abstract][Full Text] [Related]
17. [Immunophenotypic and clinical characteristic analysis of NPM1 mutated acute myeloid leukemia with a normal karyotype].
Liu YR; Lai YY; Chang Y; Ruan GR; Qin YZ; Wang YZ; Zhu HH; Shi HX; Jiang B; Jiang H; Jiang Q; Hao L; Li JL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1385-9. PubMed ID: 24370016
[TBL] [Abstract][Full Text] [Related]
18. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
19. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
[TBL] [Abstract][Full Text] [Related]
20. [Expression of TFPI-2 gene and its promoter methylation in acute myeloid leukemia].
Shao LL; Fan J; Wang R; Feng LL; Zhen CQ; Sui XH; Li Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):920-6. PubMed ID: 25130804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
